Could a short course of immunotherapy shrink colon cancer before surgery?
NCT ID NCT06830239
First seen Feb 12, 2026 · Last updated Jun 22, 2026 · Updated 20 times
Summary
This early-phase trial is testing whether giving the immunotherapy drug dostarlimab before surgery can help shrink tumors in people with a specific type of stage III colon cancer (called pMMR/MSS). Ten participants will receive two doses of the drug over six weeks, then undergo surgery. The main goal is to study molecular changes in blood and tumor tissue that might predict a better response. While some patients may benefit, it is not yet known if this approach is better than surgery alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UZLeuven
RECRUITINGLeuven, 3000, Belgium
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dostarlimab (Jemperli), an immunotherapy drug that helps the immune system fight cancer
What this could lead to
If it works, this could point toward a way to shrink certain colon cancers before surgery, possibly improving outcomes for some patients.
What could go wrong
This is a very small, early-phase trial with only 10 people. It is not yet proven to work for this type of colon cancer, and there is a risk of side effects or that the cancer may not respond.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.